

# Potent TMEM16A Small Molecule Treatment for Inflammatory and Reactive Airway Diseases, Asthma, Hypertension, Pain and Cancer

Tech ID: 29236 / UC Case 2017-138-0

## CONTACT

Todd M. Pazdera

[todd.pazdera@ucsf.edu](mailto:todd.pazdera@ucsf.edu)

tel: 415-502-1636.



## INVENTORS

- ▶ Anderson, Marc O.
- ▶ Phuan, Puay-Wah
- ▶ Verkman, Alan S.

## OTHER INFORMATION

### KEYWORDS

Thiophene-arylamides,  
AACT, TMEM16A inhibitors,  
Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel  
inhibitors

### CATEGORIZED AS

- ▶ **Medical**
  - ▶ Disease: Cancer
  - ▶ Disease:  
Cardiovascular and  
Circulatory System
  - ▶ Disease: Digestive  
System
  - ▶ Disease: Respiratory  
and Pulmonary System
  - ▶ Therapeutics

## INVENTION NOVELTY


A novel class of 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as potent TMEM16A inhibitors

## VALUE PROPOSITION

Transmembrane protein 16A (TMEM16A), also called anoctamin 1 (ANO1), is a  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  channel expressed widely in mammalian epithelia, vascular smooth muscle and electrically excitable cells. Increased TMEM16A expression is associated with COPD and asthma, and TMEM16A is reported as a biomarker for gastrointestinal stromal and esophageal tumors. Pharmacological TMEM16A inhibitors, including the AACT small molecule scaffolds described in this invention, could be used to treat diseases such as inflammatory and reactive airway diseases, hypertension, gastrointestinal hypermotility and some cancers.

The TMEM16A inhibitors developed by UCSF scientists have the following advantages:

- ▶  $\text{IC}_{50} \sim 30 \text{ nM}$ ; substantially more potent than prior compounds
- ▶ Substantially better metabolic stability and PK than prior compounds
- ▶ Demonstrated efficacy in acute hypertension, inhibition of intestinal smooth muscle contraction and inhibition of GI tumor cell growth



## TECHNOLOGY DESCRIPTION

The Verkman lab at the University of California, San Francisco has discovered, synthesized and biochemically evaluated a series of TMEM16A inhibitors. The chemical structure of the 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamide inhibitor scaffold was refined through medicinal chemistry to identify bromodifluoroacetamide-based inhibitors with enhanced potency and metabolic stability.

## LOOKING FOR PARTNERS

To develop & commercialize the TMEM16A inhibitors as therapies for inflammatory and reactive airway diseases, hypertension, gastrointestinal hypermotility and some cancers.

## STAGE OF DEVELOPMENT

Proof of Concept – in vitro and ex vivo

## DATA AVAILABILITY

Under NCD/CDA

## RELATED MATERIALS

- ▶ ["Substituted 2-Acyaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A \(TMEM16A\)." Truong, Eric C., et al., Journal of medicinal chemistry 60.11 \(2017\): 4626-4635.](#)

## PATENT STATUS

Country	Type	Number	Dated	Case
Germany	Issued Patent	3,612,180	10/11/2023	2017-138
European Patent Office	Issued Patent	3,612,180	10/11/2023	2017-138
France	Issued Patent	3,612,180	10/11/2023	2017-138
United Kingdom	Issued Patent	3,612,180	10/11/2023	2017-138
United States Of America	Issued Patent	11,358,947	06/14/2022	2017-138

## ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ [SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS](#)
- ▶ [Novel Small Molecule Drug for the Treatment of Constipation and Oxalate Kidney Stones](#)
- ▶ [Small Molecule Pendrin Inhibitors for Treatment of Inflammatory Airway Diseases and Diuretic Resistance](#)
- ▶ [Immunotherapy for Treatment of Neuromyelitis Optica \(NMO\)](#)

### ADDRESS

**UCSF**

**Innovation Ventures**

600 16th St, Genentech Hall, S-272,

San Francisco, CA 94158

### CONTACT

Tel:

[innovation@ucsf.edu](mailto:innovation@ucsf.edu)

<https://innovation.ucsf.edu>

Fax:

### CONNECT

 Follow  Connect

© 2018 - 2023, The Regents of the University of California

[Terms of use](#) [Privacy Notice](#)